Comparative Pharmacology
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus EVEKEO ODT.
DEXTROAMPHETAMINE SULFATE vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category D/X
Category C
CNS Stimulant
CNS Stimulant